Janssen shakes up reimbursement

The federal government should reimburse some innovative medicines for cancer and rare diseases before they finish Phase III trials and while HTA processes are still in negotiation, according to a report released by Janssen.

To see the whole article please log in.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here